Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Akcea Therapeutics Inc (AKCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,262,660
  • Shares Outstanding, K 92,770
  • Annual Sales, $ 64,870 K
  • Annual Income, $ -225,820 K
  • 60-Month Beta 1.63
  • Price/Sales 32.52
  • Price/Cash Flow N/A
  • Price/Book 5.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.38
  • Number of Estimates 3
  • High Estimate -0.05
  • Low Estimate -0.57
  • Prior Year -0.75
  • Growth Rate Est. (year over year) +49.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.67 +21.91%
on 05/20/19
25.32 -5.29%
on 06/18/19
+3.30 (+15.96%)
since 05/17/19
3-Month
19.67 +21.91%
on 05/20/19
32.57 -26.37%
on 04/05/19
-6.14 (-20.39%)
since 03/18/19
52-Week
19.67 +21.91%
on 05/20/19
40.75 -41.15%
on 08/07/18
+0.25 (+1.05%)
since 06/18/18

Most Recent Stories

More News
Akcea Therapeutics is Now Oversold (AKCA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

AKCA : 23.98 (-1.68%)
Interesting AKCA Put And Call Options For May 17th

Investors in Akcea Therapeutics Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AKCA options...

AKCA : 23.98 (-1.68%)
Akcea Therapeutics (AKCA) Q1 Earnings and Revenues Lag Estimates

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -72.58% and -7.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AKCA : 23.98 (-1.68%)
Akcea Therapeutics: 1Q Earnings Snapshot

BOSTON (AP) _ Akcea Therapeutics Inc. (AKCA) on Wednesday reported first-quarter net income of $27.2 million, after reporting a loss in the same period a year earlier.

AKCA : 23.98 (-1.68%)
Akcea Reports Financial Results and Highlights for First Quarter 2019

Achieved First Quarter 2019 TEGSEDI (inotersen) Global Net Product Revenues of $7 Million

AKCA : 23.98 (-1.68%)
IONS : 64.90 (+0.26%)
NVS : 91.30 (+1.72%)
New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

NEURO-TTR phase 3 open-label extension study showed TEGSEDI(R) (inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy

AKCA : 23.98 (-1.68%)
IONS : 64.90 (+0.26%)
Akcea and Ionis Announce Approval of WAYLIVRA(R) (volanesorsen) in the European Union

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced today that WAYLIVRA has received conditional marketing authorization...

AKCA : 23.98 (-1.68%)
IONS : 64.90 (+0.26%)
Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19)

Multiple clinical presentations at AAN focus on the long-term clinical benefits of treatment with TEGSEDI(TM) (inotersen)

AKCA : 23.98 (-1.68%)
IONS : 64.90 (+0.26%)
Akcea Therapeutics (AKCA) Earnings Expected to Grow: Should You Buy?

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AKCA : 23.98 (-1.68%)
Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that Ionis, its collaborators and Ionis' affiliate, Akcea Therapeutics, will present data on SPINRAZA®...

AKCA : 23.98 (-1.68%)
IONS : 64.90 (+0.26%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade AKCA with:

Business Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx...

See More

Key Turning Points

2nd Resistance Point 25.91
1st Resistance Point 24.95
Last Price 23.98
1st Support Level 23.39
2nd Support Level 22.79

See More

52-Week High 40.75
Fibonacci 61.8% 32.70
Fibonacci 50% 30.21
Fibonacci 38.2% 27.72
Last Price 23.98
52-Week Low 19.67

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar